- Company
- Severe asthma drug 'Fasenra' lands in general hospitals
- by Eo, Yun-Ho Jul 15, 2024 05:47am
- ‘Fasenra,’ a severe asthma treatment, has been listed for insurance reimbursement this month and is now available for prescriptions at general hospitals. Industry sources said that AstraZeneca Korea’s Fasenra (benralizumab) has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Center in Seoul, Se
- Company
- K-Bios make progress in new rare lung cancer drug dev
- by Son, Hyung-Min Jul 15, 2024 05:47am
- The c-MET-mutation-targeted NSCLC drugs that are being developed by Korean pharma and biotech companies have been recognized for their potential. Recently, Abion Bio signed an agreement with Janssen to receive Leclaza (lasertinib) free of charge. This agreement will allow Abion Bio to commercialize the combination of its in-development vabamet
- Company
- K-Bio speeds up novel drug development to treat MASH
- by Son, Hyung-Min Jul 15, 2024 05:47am
- The biotech industry in South Korea has made notable achievements in treating MASH. Many pharmaceutical companies have failed in clinical trials to develop a treatment for MASH due to its complex pathogenesis. As the first treatment for MASH has been approved, the industry draws attention to the success of the commercialization of other new drug
- Opinion
- [Reporter’s View] MFDS provides support for drug shortages
- by Lee, Hye-Kyung Jul 15, 2024 05:47am
- A thyroid cancer treatment ‘Theracap’ was once listed on a “Drug Shortages Database,” where suspension of the supply or shortages are listed as current, of the Ministry of Food and Drug Safety (MFDS)’s Drug Safety website and then removed. Saehan Industry expected the drug shortage and notified the MFDS of its suspension in accordance w
- Policy
- Roche Korea speeds up reimb of Ocrevus in KOR
- by Lee, Tak-Sun Jul 12, 2024 05:48am
- Roche Korea is making active moves to receive reimbursement for its multiple sclerosis drug Ocrevus, which was approved in May this year. Roche, which applied for reimbursement immediately after the approval, has set out to persuade the Health Insurance Review and Assessment Service to expedite the application process. According to in
- Company
- Protein C deficiency drug 'Ceprotin' begins negotiations
- by Eo, Yun-Ho Jul 12, 2024 05:48am
- 'Ceprotin' has entered the last stage of obtaininig reimbursement listing. According to our investigation, Takeda Pharmaceuticals Korea has started to negotiate drug pricing with the National Health Insurance Service (NHIS) for Ceprotin (Human potein C), a novel drug for the treatment of congenital protein C deficiency. ‘Human protei
- Policy
- Reassessing the plan for comparing foreign drug prices
- by Lee, Tak-Sun Jul 12, 2024 05:48am
- The government will likely reassess foreign drug price comparison by evaluating the therapeutic category with the highest number of products. Consequently, gastrointestinal agents, high blood pressure drugs, and antibiotics will be assessed in the first year. There are over 2000 products in these three therapeutic categories. Furthermore
- Company
- Will Epkinly become a game-changer in the blood cancer mkt?
- by Hwang, Byung-woo Jul 12, 2024 05:47am
- The arrival of bispecific antibody-based therapies in Korea is expected to shift the blood cancer treatment market paradigm. The industry is welcoming the introduction of a new treatment option, as an unmet need exists in diffuse large B-cell lymphoma (DLBCL), which has a poor prognosis even after three or later lines of treatments. Ab
- Policy
- ‘Bioequivalence tests rather intensified price cuts'
- by Lee, Tak-Sun Jul 12, 2024 05:47am
- The pharmaceutical industry is calling for improvements as their drugs that have completed bioequivalence tests per the government’s insurance price ceiling reevaluations may face larger price cuts under ‘Type C’ of the Price Volume Agreement negotiations this year. Generic drugs that have completed bioequivalence tests during the i
- Company
- "Enhertu gets expanded indication to treat lung cancer"
- by Son, Hyung-Min Jul 11, 2024 06:12am
- “Previously, patients could only use Enhertu by participating in clinical trials conducted in tertiary general hospitals. Current approval in South Korea will provide a new treatment option for patients with HER2 mutant metastatic non-small cell lung cancer (NSCLC). Brain metastasis is common in lung cancer patients. Because Enhertu demonst
